Solid Biosciences Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for SLDB, updated each market day.
SLDB AI Sentiment
AI sees no strong directional signal for Solid Biosciences Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Solid Biosciences Inc. Common Stock
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Sector
Exchange
Market Cap
$796,969,643
Cap Tier
Employees
121
Headquarters
CHARLESTOWN, MA
Listed Since
Jan. 25, 2018
Website
SLDB Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SLDB Volatility
Solid Biosciences Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
